HURA · XBRL financial data
TuHURA Biosciences financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (HURA's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | †Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | year only | 0 | 0* | 0* | 0* | 0 | 0* | 0* | 0* | 0 | — |
| Research and development | 2 | 0 | 1 | 3 | 0 | 4* | 5 | 5 | 5 | 6* | 5 | 7 |
| General and administrative | 1 | 1 | 1 | 1 | 2 | 2* | 2 | 5 | 2 | (2)* | 2 | 2 |
| Total operating expenses | 3 | 1 | 2 | 4 | 2 | 6* | 7 | 10 | 7 | 8* | 8 | 9 |
| Other operating income (expense) | 0 | 0 | 0 | 0* | 0 | — | — | — | — | — | — | — |
| Interest expense | — | year only | 0 | 1 | 2 | 1* | — | 0 | 0 | 1* | 0 | 0 |
| Other income (expense) | — | year only | (0) | (2) | (2) | (0)* | 0 | 0 | (0) | 1* | (0) | (0) |
| Income tax expense (benefit) | — | year only | — | — | — | year only | — | — | — | year only | — | — |
| Net income (loss) | (3) | (1) | (2) | (5) | (2) | (6)* | (7) | (10) | (7) | (7)* | (8) | (9) |
| Earnings per share, basic USD per share | (1.83) | (0.24) | (0.05) | (0.43) | (1.37) | — | (0.15) | (0.21) | (0.14) | (0.13)* | (0.13) | (0.14) |
| Earnings per share, diluted USD per share | — | — | (0.40) | (0.43) | (0.54) | — | (0.15) | (0.21) | (0.14) | (0.13)* | (0.13) | (0.14) |
| Weighted average shares, basic millions of shares | 2 | 4 | 45 | 12 | 2 | 17* | 43 | 45 | 51 | 53* | 60 | 64 |
| Weighted average shares, diluted millions of shares | — | — | 12 | 12 | 12 | — | 43 | 45 | 51 | 53* | 60 | 64 |
- † Share count changed about 1/968 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal quarters (HURA's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | †Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | 0 | 1 | 6 | 5 | 3 | 13 | 6 | 9 | 3 | 4 | 6 | 1 |
| Total current assets | 1 | 1 | 7 | 6 | 3 | 20 | 14 | 13 | 4 | 5 | 7 | 2 |
| Property and equipment, net | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Right-of-use asset | — | 0 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | — | — | — | — | — | — | — | 14 | 14 | 11 | 11 | 11 |
| Total assets | 1 | 2 | 7 | 6 | 4 | 20 | 15 | 35 | 26 | 27 | 30 | 32 |
| Accounts payable | — | 2 | — | 1 | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 3 |
| Accrued liabilities | — | 1 | — | 1 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 1 |
| Total current liabilities | 3 | 2 | 1 | 2 | 2 | 5 | 5 | 15 | 9 | 6 | 6 | 9 |
| Lease liability, non-current | — | — | — | — | — | 0 | — | — | — | 0 | 0 | 0 |
| Total liabilities | 4 | 2 | 2 | 2 | 2 | 5 | 5 | 15 | 9 | 6 | 7 | 13 |
| Accumulated deficit | (155) | (156) | (158) | (160) | (162) | (111) | (118) | (127) | (134) | (141) | (149) | (158) |
| Total stockholders' equity | (2) | (0) | 6 | 4 | 2 | 15 | 10 | 19 | 17 | 21 | 23 | 19 |
| Total liabilities and equity | 1 | 2 | 7 | 6 | 4 | 20 | 15 | 35 | 26 | 27 | 30 | 32 |
| Common shares outstanding (cover page) millions of shares | 3,388 | 39,038 | 55,305 | 55,661 | 42,285 | 44 | 44 | 50 | 51 | 64 | 64 | 64 |
- † Share count changed about 1/968 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal quarters (HURA's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | †Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (3) | (1) | (2) | (5) | (2) | (6)* | (7) | (10) | (7) | (7)* | (8) | (9) |
| Stock-based compensation | — | year only | 0 | 0* | 0* | 1* | 1 | 1* | 1* | 2* | 3 | 2* |
| Depreciation and amortization | — | year only | 0 | 0* | 0* | 0* | 0 | 0* | 0* | 0* | 0 | 0* |
| Net cash from operating activities | (1) | (2)* | (4) | (5)* | (2) | (3)* | (5) | (6)* | (11)* | (6)* | (4) | (9)* |
| Purchases of property and equipment | — | year only | — | — | 0* | 0* | 0 | 0* | 0* | 0* | 0 | 0* |
| Net cash from investing activities | — | year only | 0* | 0* | (5)* | (1)* | (1) | (0)* | 0* | (0)* | (0) | (0)* |
| Proceeds from issuing common stock | — | — | — | — | — | 0* | — | — | 6* | 6* | 8 | 0* |
| Share repurchases | — | year only | — | — | — | — | — | — | — | — | — | — |
| Net cash from financing activities | (0) | 3* | 5 | 13* | 16* | (4)* | (1) | 9* | 5* | 7* | 7 | 3* |
| Net change in cash | (1) | 0* | 1 | 8* | (2) | (7)* | (6) | 2* | (6)* | 1* | 3 | (5)* |
- † Share count changed about 1/968 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| TuHURA Biosciences | 1 | not reported | (8.6)* | 63.7M | 0.1 quarters | 10-QJun 30, 2026 |
| Enanta Pharmaceuticals | 33 | 14 | (10)* | 29.1M | 19.0 quarters | 10-QJun 30, 2026 |
| Protara Therapeutics | 17 | not reported | (15)* | 59.1M | 9.3 quarters | 10-QJun 30, 2026 |
| Caribou Biosciences | 26 | 1.5 | (23)* | 107.2M | 4.9 quarters | 10-QJun 30, 2026 |
| Fate Therapeutics | 32 | 2.1 | (23) | 119.8M | 6.6 quarters | 10-QJun 30, 2026 |
| Galectin Therapeutics | 13 | not reported | (2.4)* | 100.8M | 5.4 quarters | 10-QJun 30, 2026 |
| Protalix BioTherapeutics | 27 | 20 | (10)* | 80.6M | 2.6 quarters | 10-QJun 30, 2026 |
| Cartesian Therapeutics | 148 | 0 | (21)* | 30.3M | 7.0 quarters | 10-QJun 30, 2026 |
| Atossa Therapeutics | 26 | not reported | (9.6)* | 10.0M | 2.7 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.